Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visual function in prolactinoma patients treated with bromocriptine.

M L Moster, P J Savino, N J Schatz

    Ophthalmology
    |October 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ophthalmic presentation of giant cell arteritis in African-Americans.

    Eye (London, England)·2016
    Same author

    Idiopathic elevated episcleral venous pressure and open-angle glaucoma.

    The British journal of ophthalmology·2008
    Same author

    Association of a nonsynonymous single-nucleotide polymorphism of matrix metalloproteinase 9 with giant cell arteritis.

    Arthritis and rheumatism·2008
    Same author

    Anterior ischaemic optic neuropathy after rotator cuff surgery.

    The British journal of ophthalmology·2006
    Same author

    Tobacco-alcohol amblyopia: a maculopathy?

    The British journal of ophthalmology·2005
    Same author

    Multifocal ERG in ethambutol associated visual loss.

    The British journal of ophthalmology·2005

    Bromocriptine effectively treats visual dysfunction in most patients with prolactin-secreting pituitary adenomas (prolactinoma). This therapy led to tumor shrinkage and improved vision in nine out of ten patients studied.

    Area of Science:

    • Endocrinology
    • Neurosurgery
    • Ophthalmology

    Background:

    • Prolactin-secreting pituitary adenomas (prolactinoma) can cause significant visual dysfunction.
    • Medical management is often the first-line treatment for these tumors.

    Purpose of the Study:

    • To evaluate the efficacy of bromocriptine in patients with prolactinoma and visual impairment.
    • To assess the impact of bromocriptine on tumor size and serum prolactin levels.

    Main Methods:

    • Ten patients with prolactinoma and visual dysfunction were treated with bromocriptine.
    • Tumor size was monitored using computed tomography (CT).
    • Serum prolactin levels (SPL) were measured regularly.

    Main Results:

    Related Experiment Videos

    • Nine out of ten patients experienced visual improvement (visual field or acuity) with bromocriptine therapy.
    • CT scans showed decreased tumor size and SPL normalized in responding patients.
    • Visual improvement was observed within days of treatment initiation.
    • One patient relapsed at 11 months; two patients underwent surgery with no visual improvement.

    Conclusions:

    • Bromocriptine is an effective short- and long-term treatment for visual dysfunction caused by prolactinoma.
    • The medication demonstrates significant efficacy in reducing tumor size and improving visual outcomes.
    • Surgical intervention (trans-sphenoidal hypophysectomy) was less effective for visual improvement in this cohort.